By Elric Langton | 23 February 2024
Mike, Alex and I have a financial interest in SkinBioTherapeutics.
While today's initial outcomes from the acne study are noteworthy, surpassing even the previous achievements of the psoriasis probiotic, the enthusiasm is dampened by the sombre mood of investors. Their reluctance to engage with SkinBioTherapeutics shares is palpable, overshadowed by the looming uncertainty of the Convertible bond, which casts a shadow over the proceedings, reminiscent of an unwelcome guest at a Sunday luncheon.